NCT00507169已完成2 期
SVT-40776 in Patients Suffering From Overactive Bladder Syndrome
Salvat0 个研究点开始时间: 2006年9月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
研究概览
简要总结
The study will examine which dose of SVT-40776 is best in terms of efficacy, safety and tolerability compared to placebo and tolterodine
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients suffering from OAB for at least 6 months prior to inclusion
排除标准
- •Pregnant and breastfeeding women
- •Any medical condition or need for co-medication which interferes with the drug under investigation (SVT-40776) or the comparator (tolterodine)
研究者
相似试验
已完成
2 期
A Dose Ranging Study To Investigate The Efficacy And Safety Of SB-742457 In Alzheimer's DiseaseAlzheimer's DiseaseNCT00224497GlaxoSmithKline380
已完成
1 期
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ABT-652 in Subjects With Excessive Daytime SleepinessSleep DisorderNCT01124851Abbott36
已完成
2 期
BHV-7000 Acute Treatment of Bipolar ManiaBipolar DisorderNCT06419582Biohaven Therapeutics Ltd.274
已完成
2 期
SB-742457 And Donepezil In Alzheimer's DiseaseAlzheimer's DiseaseNCT00348192GlaxoSmithKline200
已完成
3 期
A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy and Safety of TV-44749 in Adults With SchizophreniaSchizophreniaNCT05693935Teva Branded Pharmaceutical Products R&D LLC675